
News|Articles|September 10, 2024
Ethical, Biosafety, and Scientific Review Considerations in Hematology and Oncology Clinical Trials
Author(s)WCG Clinical
The current oncology and hematology drug development pipeline features a wide array of large molecule therapeutics. As a result, clinical trial protocols have grown more complex, requiring sponsors, CROs, and research sites to tackle a variety of challenges that were less common with older, more traditional therapies.
Trending on Applied Clinical Trials Online
1
2026 DIA Global Annual Meeting: Why Protocol Digitization Has Been So Hard to Automate—Until Now
2
2026 DIA Global Annual Meeting: What the FDA's Real-Time Data Push Actually Means for Sponsors and CROs
3
One Strategy, Two Jurisdictions: Unlocking Efficiency Across EU CTR and UK Regulatory Reform
4
ACT Brief: Real-Time Data Harmonization Infrastructure, Modern Trial Payments, and SCLC Drug Confirmatory Failure
5